Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 2
1977 1
1978 1
1979 5
1980 5
1981 3
1982 2
1983 8
1984 10
1985 7
1986 13
1987 16
1988 28
1989 17
1990 22
1991 24
1992 24
1993 19
1994 19
1995 18
1996 9
1997 19
1998 15
1999 21
2000 16
2001 11
2002 20
2003 12
2004 9
2005 17
2006 17
2007 16
2008 14
2009 20
2010 28
2011 27
2012 31
2013 27
2014 18
2015 20
2016 26
2017 24
2018 21
2019 18
2020 18
2021 18
Text availability
Article attribute
Article type
Publication date

Search Results

692 results
Results by year
Filters applied: . Clear all
Page 1
A decade of clinical development of PARP inhibitors in perspective.
Mateo J, Lord CJ, Serra V, Tutt A, Balmaña J, Castroviejo-Bermejo M, Cruz C, Oaknin A, Kaye SB, de Bono JS. Mateo J, et al. Among authors: kaye sb. Ann Oncol. 2019 Sep 1;30(9):1437-1447. doi: 10.1093/annonc/mdz192. Ann Oncol. 2019. PMID: 31218365 Free PMC article. Review.
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS. Fong PC, et al. Among authors: kaye sb. N Engl J Med. 2009 Jul 9;361(2):123-34. doi: 10.1056/NEJMoa0900212. Epub 2009 Jun 24. N Engl J Med. 2009. PMID: 19553641 Free article. Clinical Trial.
Rethinking ovarian cancer: recommendations for improving outcomes.
Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR. Vaughan S, et al. Among authors: kaye sb. Nat Rev Cancer. 2011 Sep 23;11(10):719-25. doi: 10.1038/nrc3144. Nat Rev Cancer. 2011. PMID: 21941283 Free PMC article.
Reply.
Steger B, Romano V, Kaye SB. Steger B, et al. Among authors: kaye sb. Cornea. 2016 Mar;35(3):e8. doi: 10.1097/ICO.0000000000000749. Cornea. 2016. PMID: 26840597 No abstract available.
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib.
Mateo J, Moreno V, Gupta A, Kaye SB, Dean E, Middleton MR, Friedlander M, Gourley C, Plummer R, Rustin G, Sessa C, Leunen K, Ledermann J, Swaisland H, Fielding A, Bannister W, Nicum S, Molife LR. Mateo J, et al. Among authors: kaye sb. Target Oncol. 2016 Jun;11(3):401-15. doi: 10.1007/s11523-016-0435-8. Target Oncol. 2016. PMID: 27169564 Free article. Clinical Trial.
BMJ Open Ophthalmology.
Kaye SB. Kaye SB. BMJ Open Ophthalmol. 2020 Sep 1;5(1):e000530. doi: 10.1136/bmjophth-2020-000530. eCollection 2020. BMJ Open Ophthalmol. 2020. PMID: 32923680 Free PMC article. No abstract available.
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A, Kreischer N, Thway K, Gevensleben H, Sun L, Loughney J, Chatterjee M, Toniatti C, Carpenter CL, Iannone R, Kaye SB, de Bono JS, Wenham RM. Sandhu SK, et al. Among authors: kaye sb. Lancet Oncol. 2013 Aug;14(9):882-92. doi: 10.1016/S1470-2045(13)70240-7. Epub 2013 Jun 28. Lancet Oncol. 2013. PMID: 23810788 Clinical Trial.
692 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page